Clinical trials: VTE
VTE Prophylaxis
Study Evaluating Betrixaban in Pediatric Participants
This trial was a Phase 1, open-label, multicenter study of the pharmacokinetics (PK), pharmacodynamics (PD), and safety of a single dose of betrixaban in pediatric participants at risk of venous thromboembolism (VTE).
- Trial name
- NCT03346083
- Testing
- Betrixaban
- Where
- 20 sites in United States, Russia and 2 more
- Volunteers
- 21 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Venous Thromboembolism, Pediatrics
Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events
The study will evaluate the effectiveness of a novel, real-time risk prediction model for identifying pediatric patients at risk for developing in-hospital blood clots (or venous thromboembolism [VTE]) based on data easily…
- Conditions
- Venous Thromboembolism, Pediatrics, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT04574895
- Testing
- Hematology Review
- Where
- United States
- Volunteers
- 17,427 people
- Sponsor
- Vanderbilt University Medical Center
Thromboembolism
Evaluation of the Risk of VTE Among Patients Hospitalized in Non-surgical Departments
Patients hospitalized in internal wards are at risk for VTE. The current guidelines recommend the use of thromboprophylaxis for 7-10 days among patients who are at increased risk for VTE.
- Trial name
- NCT03073915
- Volunteers
- 4,000 people
- Sponsor
- Hadassah Medical Organization
Venous Thrombosis, Pulmonary Embolism
Study Of Lybrel In Relation To Venous Thromboembolism
Lybrel® is an oral contraceptive that delivers low doses of levonorgestrel and ethinyl estradiol (90 μg/20 μg). Lybrel is taken on a continuous basis without a placebo or pill-free interval to inhibit menstrual cycle bleeding by…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Sinus Thrombosis, Intracranial
- Trial name
- NCT01297348
- Testing
- 90ug levonorgestrel / 20 ug ethinyl estradiol, Oral Contraceptives containing 20 ug of ethinyl estradiol
- Volunteers
- 598,682 people
- Sponsor
- Pfizer
Venous Thromboembolism
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
- Trial name
- NCT02464969
- Testing
- Apixaban, Standard of Care
- Where
- 128 sites in United States, Australia and 11 more
- Volunteers
- 229 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, Venous Thromboembolism
NOACs Use in AF or VTE (SUNSHINE Registry)
The outcomes regiStry for non-vitamin k antagonist oral anticoagUlants treatmeNt in variouS tHrombotIc dIseases for better cliNical practicE (SUNSHINE) is a multicenter, prospective, observational non-interventional…
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Oral Anticoagulant
- Trial name
- NCT05378308
- Testing
- Patients with Atrial Fibrillation (AF) or venous thromboembolism (VTE)
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Henan Provincial People's Hospital
Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism; Anticoagulants
VTE and the Related Factors Associated With Higher Rates of PE After a DVT in Southwestern China
Little is known about the current management status of venous thromboembolism (VTE) in Southwestern China. We aimed to investigate the status of anticoagulant administration in VTE in Southwestern China and assess the potential…
- Trial name
- NCT05464901
- Volunteers
- 500 people
- Sponsor
- Wei Huang
Venous Thromboembolism
Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
The main objectives of this large phase IIb/III paediatric study are to assess the efficacy and safety of dabigatran etexilate relative to standard of care and to document the appropriateness of the proposed dabigatran etexilate…
- Trial name
- NCT01895777
- Testing
- dabigatran etexilate, standard of care
- Where
- 65 sites in United States, Argentina and 24 more
- Volunteers
- 267 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolic Disease, Pulmonary Embolism
CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism
Although pharmacologic and mechanical methods to prevent VTE are safe, effective, cost-effective, and advocated by authoritative guidelines,many studies continue to demonstrate that these preventive methods are significantly…
- Conditions
- Venous Thromboembolic Disease, Pulmonary Embolism, Venous Thromboembolism, Deep Venous Thrombosis
- Trial name
- NCT04211181
- Testing
- The multifaceted interventions, Routine VTE prophylaxis
- Where
- China
- Volunteers
- 5,800 people
- Sponsor
- China-Japan Friendship Hospital
Deep Vein Thrombosis, Pulmonary Embolism
D-Dimer and IPG for Recurrent Thrombosis (DIRECT)
To simplify and improve the diagnostic approach to patients with clinically suspected recurrent DVT by determining whether the results of the combination of IPG and d-dimer testing, using a whole blood agglutination assay, can be…
- Trial name
- NCT00182247
- Testing
- venogram
- Where
- 8 sites in Canada, Italy
- Volunteers
- 600 people
- Sponsor
- Hamilton Health Sciences Corporation
Recruiting
VTE Risk Prevention System Based on Big Data Analysis and Multimodule System
Venous thromboembolism (VTE) is one of the most common complications in perioperative period and the most common cause of postoperative death. VTE includes deep vein thrombosis (DVT) and acute pulmonary thromboembolism (PTE).
- Trial name
- NCT05969951
- Where
- China
- Volunteers
- 100,000 people
- Sponsor
- Shengjing Hospital
Venous Thromboembolism
Development and Validation of the Patient-completed Caprini Risk Score
The investigators aimed to test the reliability and validity of the Chinese version of patient-completed CRS in hospitalized patients and to evaluate whether this form can be widely used in clinical practice instead of only…
- Trial name
- NCT04663477
- Testing
- patient-completed Caprini Risk Score
- Where
- China
- Volunteers
- 1,017 people, healthy volunteers welcome
- Sponsor
- China-Japan Friendship Hospital
Venous Thromboembolic Disease, Post Thrombotic Syndrome
Long-term Outcome After Edoxaban Versus Vitamin K Antagonists for Acute VTE
The HOKUSAI post VTE study contains of two different research questions; one on the long term outcomes of deep vein thrombosis and one on the long term effects of pulmonary embolism, post thrombotic syndrome (PTS) and chronic…
- Conditions
- Venous Thromboembolic Disease, Post Thrombotic Syndrome, Chronic Thromboembolic Pulmonary Hypertension, Quality of Life
- Trial name
- HOKUSAIpostVTE (NCT04007653)
- Testing
- Observation
- Where
- Netherlands
- Volunteers
- 1,200 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
VTE
The Mechanism and Prognosis of Pulmonary Circulation Dysfunction
Venous thromboembolism (VTE) is a condition which influenced by both environmental and genetic factors. This study is going to explore new significant Single nucleotide polymorphisms (SNPs) associated with VTE by Genome-Wide…
- Trial name
- NCT03616366
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Incidence Rate of Perioperiative Venous Thromboembolism(VTE) in Colorectal Cancer Patients
Incidence Rate of Perioperiative VTE in Colorectal Cancer Patients : a Multicenter Prospective Observational Cohort Study
This is a multi-centered, prospective, observational study aimed at observing the Incidence Rate of Perioperiative VTE in Colorectal Cancer Patients
- Trial name
- NCT04588805
- Volunteers
- 1,217 people
- Sponsor
- Beijing Friendship Hospital
Cardiovascular Diseases, Thromboembolism
Risk Factors for Venous Thromboembolism in the Community
To evaluate the trends in the incidence of venous thromboembolism, to determine the risk factors for venous thromboembolism in patients with medical and surgical illness, and to evaluate the efficacy of the anticoagulant therapy…
- Trial name
- NCT00011180
- Where
- United States
- Volunteers
- 385 people
- Sponsor
- Mayo Clinic
VTE
Exercise Training After an Acute Blood Clot
Patients after an acute blood clot in the veins are at risk for leg-related complications such as pain, swelling, and immobility.
- Trial name
- TRAIN ABC (NCT01864447)
- Testing
- VTE REHABILITATION: High-Caloric Expenditure Exercise Training (HCE) and The Dietary Behavioral Weight Loss Intervention (BWL)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Vermont
Venous Thromboembolism
Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)
The objective of this investigation is to assess safety and effectiveness of Xarelto under practice routine use in VTE secondary prevention after acute DVT, focusing on hemorrhagic-related AEs, recurrent venous thromboembolism…
- Trial name
- JPMS-XAR-VTE (NCT02558465)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Japan
- Volunteers
- 2,540 people
- Sponsor
- Bayer
Venous Thromboembolism (VTE)
Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).
Critically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary…
- Trial name
- NCT06628778
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 802 people
- Sponsor
- Johns Hopkins All Children's Hospital
Venous Thromboembolism
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
- Trial name
- NCT05966740
- Where
- 10 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim